JP2001513812A - 顔面手術におけるレボブピバカインの使用 - Google Patents
顔面手術におけるレボブピバカインの使用Info
- Publication number
- JP2001513812A JP2001513812A JP53826998A JP53826998A JP2001513812A JP 2001513812 A JP2001513812 A JP 2001513812A JP 53826998 A JP53826998 A JP 53826998A JP 53826998 A JP53826998 A JP 53826998A JP 2001513812 A JP2001513812 A JP 2001513812A
- Authority
- JP
- Japan
- Prior art keywords
- levobupivacaine
- surgery
- bupivacaine
- administered
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 title claims abstract description 39
- 229960004288 levobupivacaine Drugs 0.000 title claims abstract description 37
- 238000001356 surgical procedure Methods 0.000 title claims abstract description 17
- 230000001815 facial effect Effects 0.000 title claims abstract description 6
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 5
- 230000037005 anaesthesia Effects 0.000 claims abstract description 5
- 230000036592 analgesia Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229960003150 bupivacaine Drugs 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940127558 rescue medication Drugs 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004357 third molar Anatomy 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- LEBVLXFERQHONN-MRXNPFEDSA-N dextrobupivacaine Chemical compound CCCCN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-MRXNPFEDSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704352.5A GB9704352D0 (en) | 1997-03-03 | 1997-03-03 | Levobupivacaine and its use |
| GB9704352.5 | 1997-03-03 | ||
| PCT/GB1998/000657 WO1998038996A1 (en) | 1997-03-03 | 1998-03-03 | The use of levobupivacaine in facial surgery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001513812A true JP2001513812A (ja) | 2001-09-04 |
| JP2001513812A5 JP2001513812A5 (enExample) | 2005-08-11 |
Family
ID=10808603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53826998A Pending JP2001513812A (ja) | 1997-03-03 | 1998-03-03 | 顔面手術におけるレボブピバカインの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5919804A (enExample) |
| EP (1) | EP0981347B1 (enExample) |
| JP (1) | JP2001513812A (enExample) |
| KR (1) | KR100516676B1 (enExample) |
| CN (1) | CN1089585C (enExample) |
| AT (1) | ATE240730T1 (enExample) |
| AU (1) | AU730390B2 (enExample) |
| BR (1) | BR9808303A (enExample) |
| CA (1) | CA2279497C (enExample) |
| DE (1) | DE69814851T2 (enExample) |
| DK (1) | DK0981347T3 (enExample) |
| ES (1) | ES2199423T3 (enExample) |
| GB (1) | GB9704352D0 (enExample) |
| HU (1) | HU225151B1 (enExample) |
| IL (1) | IL131084A0 (enExample) |
| NO (1) | NO322446B1 (enExample) |
| PL (1) | PL190900B1 (enExample) |
| PT (1) | PT981347E (enExample) |
| WO (1) | WO1998038996A1 (enExample) |
| ZA (1) | ZA981779B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998286A2 (en) * | 1997-07-21 | 2000-05-10 | Darwin Discovery Limited | Use of levobupivacaine |
| WO1999004772A2 (en) * | 1997-07-22 | 1999-02-04 | Darwin Discovery Limited | Use of levobupivacaine |
| US20020039596A1 (en) | 1997-11-14 | 2002-04-04 | Hartoun Hartounian | Production of multivesicular liposomes |
| WO2000003660A1 (en) | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| IL158819A0 (en) * | 2001-05-31 | 2004-05-12 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
| SI1534313T1 (sl) | 2002-07-30 | 2013-03-29 | Omeros Corporation | Oftalmološke raztopine in postopek za izpiranje |
| DE10260313A1 (de) * | 2002-12-20 | 2004-07-15 | Siemens Ag | Elektrische Maschine mit Wicklungen aus Litze |
| US20050176823A1 (en) * | 2004-02-10 | 2005-08-11 | Diaz Robert L. | Intra-operative procedure for post-operative pain control |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12151024B2 (en) | 2021-01-22 | 2024-11-26 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| GB2627096A (en) | 2021-10-14 | 2024-08-14 | Pacira Pharmaceuticals Inc | Bupivacaine multivesicular liposome formulations and uses thereof |
| US12070454B1 (en) | 2022-05-05 | 2024-08-27 | Pfof Llc | Anesthetic nerve block and method |
| IL316770A (en) | 2022-05-05 | 2025-01-01 | Pfof Llc | Nerve block anesthesia and method |
| US12251472B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12246092B1 (en) | 2024-05-20 | 2025-03-11 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12280149B1 (en) | 2024-05-20 | 2025-04-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695576A (en) * | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
| ATE210982T1 (de) * | 1993-10-13 | 2002-01-15 | Darwin Discovery Ltd | Analgetisches mittel und dessen verwendung |
| GB9321061D0 (en) * | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
| DE69628743T2 (de) * | 1995-04-13 | 2004-05-13 | Darwin Discovery Ltd., Slough | Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen |
-
1997
- 1997-03-03 GB GBGB9704352.5A patent/GB9704352D0/en active Pending
-
1998
- 1998-03-03 ZA ZA981779A patent/ZA981779B/xx unknown
- 1998-03-03 AT AT98908223T patent/ATE240730T1/de active
- 1998-03-03 JP JP53826998A patent/JP2001513812A/ja active Pending
- 1998-03-03 KR KR10-1999-7007975A patent/KR100516676B1/ko not_active Expired - Lifetime
- 1998-03-03 AU AU66304/98A patent/AU730390B2/en not_active Expired
- 1998-03-03 CN CN98802994A patent/CN1089585C/zh not_active Expired - Lifetime
- 1998-03-03 WO PCT/GB1998/000657 patent/WO1998038996A1/en not_active Ceased
- 1998-03-03 EP EP98908223A patent/EP0981347B1/en not_active Expired - Lifetime
- 1998-03-03 DK DK98908223T patent/DK0981347T3/da active
- 1998-03-03 PL PL335561A patent/PL190900B1/pl unknown
- 1998-03-03 IL IL13108498A patent/IL131084A0/xx not_active IP Right Cessation
- 1998-03-03 HU HU0000873A patent/HU225151B1/hu unknown
- 1998-03-03 BR BR9808303-1A patent/BR9808303A/pt not_active Application Discontinuation
- 1998-03-03 ES ES98908223T patent/ES2199423T3/es not_active Expired - Lifetime
- 1998-03-03 US US09/033,917 patent/US5919804A/en not_active Expired - Lifetime
- 1998-03-03 DE DE69814851T patent/DE69814851T2/de not_active Expired - Lifetime
- 1998-03-03 PT PT98908223T patent/PT981347E/pt unknown
- 1998-03-03 CA CA002279497A patent/CA2279497C/en not_active Expired - Lifetime
-
1999
- 1999-09-02 NO NO19994257A patent/NO322446B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE240730T1 (de) | 2003-06-15 |
| CA2279497C (en) | 2009-01-20 |
| ZA981779B (en) | 1999-03-03 |
| IL131084A0 (en) | 2001-01-28 |
| WO1998038996A1 (en) | 1998-09-11 |
| KR100516676B1 (ko) | 2005-09-22 |
| HU225151B1 (en) | 2006-07-28 |
| AU730390B2 (en) | 2001-03-08 |
| DE69814851T2 (de) | 2004-01-22 |
| AU6630498A (en) | 1998-09-22 |
| NO994257D0 (no) | 1999-09-02 |
| CN1249684A (zh) | 2000-04-05 |
| ES2199423T3 (es) | 2004-02-16 |
| PL190900B1 (pl) | 2006-02-28 |
| DK0981347T3 (da) | 2003-09-15 |
| EP0981347B1 (en) | 2003-05-21 |
| NO994257L (no) | 1999-11-02 |
| HK1022651A1 (en) | 2000-08-18 |
| PL335561A1 (en) | 2000-05-08 |
| US5919804A (en) | 1999-07-06 |
| BR9808303A (pt) | 2000-05-16 |
| KR20000075896A (ko) | 2000-12-26 |
| PT981347E (pt) | 2003-09-30 |
| CN1089585C (zh) | 2002-08-28 |
| HUP0000873A2 (hu) | 2000-09-28 |
| HUP0000873A3 (en) | 2002-10-28 |
| CA2279497A1 (en) | 1998-09-11 |
| GB9704352D0 (en) | 1997-04-23 |
| NO322446B1 (no) | 2006-10-09 |
| DE69814851D1 (de) | 2003-06-26 |
| EP0981347A1 (en) | 2000-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5849763A (en) | Use of levobupivacaine as an anesthetic agent | |
| JP2001513812A (ja) | 顔面手術におけるレボブピバカインの使用 | |
| JP2001510795A (ja) | レボブピバカインとその使用 | |
| JPH09503778A (ja) | 鎮痛剤およびその使用 | |
| KR100535554B1 (ko) | 소아과 수술에서의 레보부피바카인의 용도 | |
| JP2001510794A (ja) | レボブピバカインとその使用 | |
| AU731127B2 (en) | The use of levobupivacaine or ropivacaine in treating migraine | |
| CA2216583C (en) | Levobupivacaine and its use as an anaesthetic in pregnant women | |
| JP3792251B2 (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| HUP0100599A2 (hu) | Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen | |
| WO1998038997A1 (en) | Use of levobupivacaine in combination with opiods or alfa2-agonists for providing anaesthesia or analgesia | |
| MXPA99008055A (es) | Uso de levobupivacaina en cirugia facial | |
| HK1022651B (en) | The use of levobupivacaine in facial surgery | |
| Khalil et al. | Alfentanil decreases the excitatory phenomena of sodium methohexital | |
| KR100413717B1 (ko) | 레보부피바카인및임산부의마취제로서그것의용도 | |
| Abdelmonem et al. | COMPARISON BETWEEN INTRATHECAL ISOBARIC LEVOBUPIVACAINE VERSUS HYPERBARIC BUPIVACAINE IN ELDERLY PATIENTS UNDERGOING TROCHANTERIC FRACTURE SURGERY | |
| UA146303U (uk) | Спосіб симптоматичного лікування болю | |
| MXPA99008056A (en) | The use of levobupivacaine or ropivacaine in treating migraine | |
| Schug et al. | Local anesthetics | |
| JPH09136843A (ja) | 血圧上昇薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090303 |